Navigation Links
Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
Date:1/19/2010

JERUSALEM, Jan. 19 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Chiasma.

The two companies have initiated a feasibility program funded by Novartis. Should Novartis exercise the option, it would assume the global clinical development, manufacturing, regulatory submissions and commercialization of the products containing the TPE technology. Chiasma would receive payments upon the option exercise and upon successful completion of certain development and regulatory milestones. In addition, Chiasma would be eligible to receive a percentage of any incremental profits generated as a result of the incorporation of the TPE technology into these Novartis products. Additional terms were not disclosed.

Fredric Price, Chairman and CEO of Chiasma said, "Our strategy is two-fold: (1) to develop our own proprietary products and seek out partnerships after demonstrating clinical effectiveness and safety; and (2) to enter into arrangements with companies whose important drugs could benefit from the TPE technology.

"Our internally-developed pipeline is focused on developing new therapies by selecting approved macromolecules that are currently available in injectable form, changing the route of administration to oral and evaluating them for new indications, thereby creating new drugs that will take advantage of the 505(b)(2) regulatory route in the US and similar regulations in other countries.'/>"/>

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
2. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
3. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
4. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
5. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
6. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
7. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
8. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
9. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... letter is being released by CEL-SCI Corporation (NYSE Alternext ... Shareholders: , I am writing today to provide you with ... on our plans for dealing with the current financial downturn. ... year of meaningful accomplishments which put CEL-SCI in a valuable ...
... Md., Feb. 19 Hospital associations in 10 ... program to test methods of reducing central-line associated ... (ICUs), according to HHS, Agency for Healthcare Research ... Nebraska, North Carolina, Ohio, Pennsylvania, Texas, and Washington. ...
Cached Medicine Technology:CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 510-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 210-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 3
(Date:4/18/2014)... prepped to enter the battle against infectious disease. ... in remote areas, thanks in part to knowledge ... International Space Station on the behavior of liquids. ... flow to diagnose infectious diseases such as HIV/AIDS ... at Northwestern University in Evanston, Ill., had been ...
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... America, Inc.,(OTC Bulletin Board: CBAI), the umbilical cord ... on bringing the life,saving potential of stem cells ... for the first quarter of 2008, ended March ... umbilical cord,blood storage business increased 10 percent while ...
... 20 Accelerate Brain Cancer,Cure ( http://www.abc2.org ) ... brain cancer specialists covering important updates on,advancements in ... for newly,diagnosed brain cancer patients., The videos ... the worlds,leading researchers in the fields of brain ...
... May 20 Mayo Clinic researchers,found that the ... is approximately the same at a,multidisciplinary medical center ... rate for 211 hospitals in the National Healthcare ... because it suggests that,care levels are generally strong ...
... Data presented today at the International Conference ... that Perforomist™ Inhalation Solution (formoterol fumarate inhalation ... profile that is comparable to the dry ... Foradil® Aerolizer® 12 g (FA). , ...
... The Board of,Directors of BD (Becton, Dickinson and Company) ... 28.5 cents per common share. The dividend will be,payable ... June 9, 2008. The,indicated annual dividend rate is $1.14 ... global medical technology company that manufactures and,sells medical devices, ...
... the following statement today following reports on Senator Ted,Kennedy,s ... been met with great concern., "Senator Kennedy is ... a,great fighter for America,s children, workers and seniors., ... well in this,challenge., "Our thoughts and prayers are ...
Cached Medicine News:Health News:Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase 2Health News:Brain Cancer Science and Treatment Information 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Perforomist-comparable pharmacokinetic and pharmacodynamic profile to DPI formulation 2
... system is an automated solution that identifies the patient, tying all critical information to the patient's unique bar-coded ... ... ... ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... direct thermal wristband ideal for positive ... admissions. Its clip closures provide a ... white for color coding. Designed specifically ... peak performance. Print high-quality text and ...
... The DataMate Laser ... System consists of laser-printable ... closure wristband and laser ... paperwork. The wristbands clear, ...
Medicine Products: